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Cell-penetrating peptides have been shown to translocate across
eukaryotic cell membranes through a temperature-insensitive and
energy-independent mechanism that does not involve membrane
receptors or transporters. Although cell-penetrating peptides have
been successfully used to mediate the intracellular delivery of a
wide variety of molecules of pharmacological interest both in vitro
and in vivo, the mechanisms by which cellular uptake occurs
remain unclear. In the face of recent reports demonstrating that
uptake of cell-penetrating peptides occurs through previously
described endocytic pathways, or is a consequence of fixation
artifacts, we conducted a critical re-evaluation of the mechanism
responsible for the cellular uptake of the S413-PV karyophilic cell-
penetrating peptide. We report that the S413-PV peptide is able to
accumulate inside live cells very efficiently through a rapid, dose-
dependent and non-toxic process, providing clear evidence that
the cellular uptake of this peptide cannot be attributed to fixation
artifacts. Comparative analysis of peptide uptake into mutant cells
lacking heparan sulphate proteoglycans demonstrates that their
presence at the cell surface facilitates the cellular uptake of the
S413-PV peptide, particularly at low peptide concentrations. Most
importantly, our results clearly demonstrate that, in addition to
endocytosis, which is only evident at low peptide concentrations,
the efficient cellular uptake of the S413-PV cell-penetrating pep-
tide occurs mainly through an alternative, non-endocytic mech-
anism, most likely involving direct penetration across cell mem-
branes.
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INTRODUCTION
Over the past years, the discovery of a number of small peptides,
defined as cell-penetrating peptides or protein transduction
domains, which are able to cross cell membranes very efficiently
through an energy-independent mechanism, has been enthusiasti-
cally considered of key interest for the development of novel thera-
peutic approaches ([1]; for a comprehensive review, see [2]).
Despite great variability in the amino acid sequence, cell-pene-
trating peptides are usually short peptide sequences rich in basic
amino acids, in some cases exhibiting the ability to be arranged
in amphipathic α-helices. The peptides derived from the HIV-1
Tat protein and from the homoeodomain of the Antennapedia pro-
tein of Drosophila (Tat and Penetratin peptides respectively) [3,4],
as well as the synthetic Pep-1 peptide [5], are among the best-
characterized cell-penetrating peptides.
Cell-penetrating peptides have been successfully used for the
intracellular delivery of different cargoes [6], including nano-
particles [7], full-length proteins [8–10], bacteriophages [11]
and liposomes [12]. Moreover, efficient delivery was achieved
in vivo upon intraperitoneal injection of fusion proteins, resulting
in successful transduction in all animal tissues, including the brain
[10].
Consistent with the capacity of cell-penetrating peptides and
of their conjugates to enter into a wide variety of cell types from
different tissues and organisms, the GAG (glycosaminoglycan)
moieties of the ubiquitous cell surface heparan sulphate proteo-
glycans have been identified as playing an important role in
mediating electrostatic interactions between cell-penetrating pep-
tides and biological membranes [13,14].
Despite the extensive use of cell-penetrating peptides for
delivery purposes, the exact mechanisms underlying their cellular
uptake and that of peptide conjugates remain poorly understood,
and are the object of some controversy. Contradicting initial ob-
servations, recent reports have demonstrated that the massive
intracellular accumulation, and particularly the nuclear localiz-
ation observed for some of these peptides and protein conjugates,
is a consequence of artifactual observations caused by redistri-
bution of surface-bound cell-penetrating peptides upon cell
fixation [15–17]. On the other hand, results from critical re-evalu-
ations of cellular uptake under experimental conditions that
avoid artifactual observations have implicated the involvement of
well-characterized endocytic pathways, such as clathrin-mediated
endocytosis [14], caveolae-mediated endocytosis [18,19] or
macropinocytosis [20,21], in the internalization of several
peptides and peptide conjugates.
Given these conflicting results concerning the mechanisms of
peptide internalization, the main goal of the present study was to
critically re-evaluate the mechanism responsible for the uptake
of the S413-PV karyophilic cell-penetrating peptide [22]. This
peptide results from the combination of a 13-amino-acid cell-
penetrating sequence, derived from the dermaseptin S4 peptide,
with the SV40 (simian virus 40) large T antigen nuclear localiz-
ation signal. Dermaseptin S4 peptide belongs to the large family of
dermaseptins, which are antimicrobial, polycationic peptides that
have been shown to have the capacity to be arranged in amphi-
pathic α-helices in apolar solvents [23]. Table 1 compares the
sequence of the S413-PV peptide with that of other cell-penetrating
peptides.
The results presented here demonstrate that the S413-PV peptide
is able to accumulate inside cells through a rapid and very
efficient process, independently of cell fixation. In contrast with
previous reports on the cellular uptake of the S413-PV peptide [22],
we show that the intracellular accumulation of this peptide is
Abbreviations used: DMEM, Dulbecco’s modified Eagle’s medium; GAG, glycosaminoglycan; GFP, green fluorescent protein; HA, haemagglutinin;
LacCer, lactosylceramide; MβCD, methyl-β-cyclodextrin.
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Table 1 Comparison of the S413-PV peptide sequence with those of cell-
penetrating peptides commonly used for cargo delivery
The SV40 large T antigen nuclear localization signal is underlined in the Pep-1 and S413-PV
peptides.
Peptide Sequence
Penetratin RQIKIWFQNRRMKWKK
Tat YGRKKRRQRRR
Pep-1 KETWWETWWTEWSQPKKKRKVC-NH2
S413-PV ALWKTLLKKVLKAPKKKRKV-NH2
temperature-sensitive and energy-dependent. Additionally, we
demonstrate that, depending on peptide concentration, two
alternative mechanisms are responsible for the cellular uptake of
the S413-PV peptide: a GAG- and endocytosis-dependent mech-
anism, dominant at low peptide concentrations, and a GAG- and
endocytosis-independent mechanism that occurs preferentially at
high peptide concentrations. Moreover, we provide clear evidence
that the main mechanism by which the S413-PV peptide is inter-
nalized into cells is the one distinct from endocytosis, which most
likely occurs through direct penetration of the peptide across cell
membranes.
EXPERIMENTAL
Cells
HeLa (human epithelial cervical carcinoma) cells were main-
tained at 37 ◦C in 5% CO2 in DMEM (Dulbecco’s modified
Eagle’s medium)/high glucose (Sigma, St Louis, MO, U.S.A.)
supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(Biochrom KG, Berlin, Germany) and 100 units/ml penicillin and
100 µg/ml streptomycin (Sigma).
CHO-K1 and pgs A-745 Chinese hamster ovary cell lines were
grown in F-12 (Ham’s) nutrient mixture (Invitrogen, Paisley,
Scotland, U.K.) supplemented with 10% fetal bovine serum,
penicillin (100 units/ml) and streptomycin (100 µg/ml), 2 mM
L-glutamine (Sigma), 10 mM Hepes (Sigma) and 14 mM sodium
bicarbonate (Sigma).
Peptides
High purity (>95%) S413-PV peptides were obtained from
Thermo Electron (Thermo Electron GmbH, Karlsruhe, Germany).
During peptide synthesis, peptides were either fluorescently
labelled with TAMRA [5-(6)-tetramethylrhodamine], or modified
with an acetyl group at the N-terminus. Both peptides were modi-
fied by introducing a cysteine and an amide group at the C-ter-
minus.
Freeze-dried peptides were reconstituted in high-purity water,
and peptide quantification was performed by using the BCA Pro-
tein Assay (Pierce, Rockford, IL, U.S.A.) and by measuring light
absorption at 280 nm.
Peptide uptake and cytotoxicity studies
For experiments on peptide uptake, 0.8 × 105 cells/well were
seeded on to 12-well plates (flow cytometry experiments) or
12-well plates containing 16 mm glass coverslips (confocal
microscopy experiments) 24 h before incubation with the peptide.
The cells were then washed with PBS and incubated with S413-PV
peptide in DMEM supplemented, or not, with 10% fetal bovine
serum.
To study the effect of low temperature on the cellular uptake
of the S413-PV peptide, HeLa cells were washed with PBS and
pre-incubated in serum-free DMEM for 1 h at 4 ◦C. The cells were
then incubated with the peptide in serum-free medium for 1 h at
4 ◦C.
For energy-depletion studies, the cells were washed with PBS
and pre-incubated for 1 h at 37 ◦C in energy-depletion medium
[glucose-free DMEM (Invitrogen)/6 mM 2-deoxy-D-glucose
(Sigma)/10 mM sodium azide (Sigma)] supplemented with 10%
fetal bovine serum [24,25], followed by incubation with the
peptide in the same medium for 1 h at 37 ◦C.
To address the effect of different drugs on the uptake of the S413-
PV peptide, cells were washed with PBS and then pre-treated
for 30 min at 37 ◦C in serum-free DMEM with: (i) 30 µM
chlorpromazine; (ii) 5 mM MβCD (methyl-β-cyclodextrin);
(iii) 25 µg/ml nystatin; (iv) 5 µg/ml filipin; (v) 5 mM amiloride;
(vi) 5 µM cytochalasin D; or (vii) 0–25 µg/ml heparin (sodium
salt from bovine intestinal mucosa; all drugs were obtained from
Sigma). The cells were then incubated with the peptide in the pre-
sence of each drug for 1 h at 37 ◦C in serum-free medium.
Parallel experiments were performed to address the effect
of these drugs (with the exception of heparin) on the cellular
uptake of transferrin, a known marker of clathrin-mediated endo-
cytosis (25 µg/ml; 30 min incubation with Alexa Fluor 546
transferrin conjugate; Molecular Probes Europe BV, Leiden, The
Netherlands), and of LacCer (lactosylceramide), a marker of raft/
caveolae-dependent endocytosis (500 nM; 10 min incubation with
BODIPY®-LacCer conjugate; Molecular Probes).
Analysis of peptide internalization was performed by confocal
laser-scanning microscopy and/or flow cytometry. Cellular uptake
of fluorescently labelled transferrin and BODIPY®-LacCer was
evaluated by flow cytometry.
Cell toxicity caused by the S413-PV peptide under all experi-
mental conditions was evaluated by flow cytometry.
Dynamin-K44A experiments
HeLa cells were co-transfected with plasmids encoding HA (haem-
agglutinin)-tagged dynamin-K44A [pcDNA3.1(−)HA-Dyn1-
K44A; American Type Culture Collection, Manassas, VA, U.S.A.]
and GFP (green fluorescent protein) (pEGFP-C1; Clontech, Palo
Alto, CA, U.S.A.) at a ratio of 10:1. Co-transfection of these two
plasmids allows the easy identification of transfected cells by
analysing the expression of the GFP reporter plasmid.
To address the effect of overexpression of the dynamin-K44A
dominant-negative mutant on the cellular uptake of the S413-PV
peptide, 24 h post-transfection, peptide uptake was analysed in
live cells expressing GFP by confocal microscopy.
As a control, 24 h post-transfection, the internalization of fluor-
escently labelled transferrin was evaluated by confocal micro-
scopy in cells expressing the dynamin-K44A mutant.
All transfection experiments were performed using Fugene 6
transfection reagent (Roche Molecular Biochemicals, Penzberg,
Germany) according to the manufacturer’s instructions, and 1 µg
of plasmid DNA/well.
For immunofluorescence analysis of HA-tagged dynamin-
K44A expression, cells were washed with PBS, fixed with 4%
paraformaldehyde for 15 min and rinsed with PBS. Cells were
then permeabilized with 0.2% (v/v) Triton X-100 for 2 min at
room temperature (≈20 ◦C), blocked with 3% (v/v) bovine serum
albumin in PBS at room temperature for 1 h, and incubated for
1 h at room temperature with anti-HA antibody (Santa Cruz Bio-
technology, Inc., Heidelberg, Germany) diluted 1:100 in blocking
solution. After an extensive wash with PBS, cells were incubated
with Alexa Fluor 594 goat anti-rabbit IgG antibody (Molecular
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Probes) for 1 h. Finally, coverslips were washed with PBS and
mounted on glass slides for fluorescence microscopy analysis.
Confocal microscopy
For analysis of the subcellular localization of the S413-PV peptide
in live cells, following peptide–cell incubation the cells were
washed and mounted in PBS, and immediately visualized by con-
focal microscopy.
Alternatively, the subcellular localization of the peptide was
evaluated in fixed cells. For this purpose, following peptide–cell
incubation the cells were washed with PBS, fixed with 4% para-
formaldehyde for 15 min at room temperature, rinsed again with
PBS and mounted in Vectashield mounting medium (Vector
Laboratories, Inc., Burlingame, CA, U.S.A.) for subsequent
analysis.
All observations were made using a Bio-Rad MRC 600 fluor-
escence confocal microscope equipped with an argon/krypton
laser (Bio-Rad Laboratories, Inc.).
Flow cytometry
Flow cytometry analysis under the different experimental con-
ditions was performed in live cells using a Becton Dickinson
FACSCalibur flow cytometer (BD Biosciences). Data were ob-
tained and analysed using CellQuest software (BD Biosciences).
After incubation with S413-PV peptide, transferrin or
BODIPY®-LacCer for the indicated times, the cells were washed
once with PBS and treated with trypsin (10 min, 37 ◦C) to remove
extracellular, surface-bound peptide and transferrin. The cells
were then washed further, resuspended in PBS and immediately
analysed. In the case of BODIPY®-LacCer, before trypsin treat-
ment an additional washing step was performed to remove fluor-
escent lipid present at the cell surface (six washes for 10 min; 5%
defatted bovine serum albumin), as described previously [26].
Live cells were gated by forward/side scattering from a total of
10000 events.
To evaluate the toxicity of the S413-PV peptide under the differ-
ent experimental conditions, parallel flow cytometry experiments
were performed using a non-labelled peptide, and cytotoxicity
was assessed on the basis of propidium iodide exclusion (1 µg/ml
for 30 min at room temperature).
RESULTS
Subcellular localization of S413-PV peptide is not affected
by cell fixation
Reports that peptide penetration is a consequence of artifactual
observations caused by an intracellular redistribution of surface-
bound peptides upon cell fixation have motivated the extensive
re-evaluation of the mechanisms responsible for the uptake of
cell-penetrating peptides.
To address the effect of cell fixation on the internalization of the
S413-PV peptide, its cellular uptake was examined both in live and
fixed cells by confocal laser-scanning microscopy. As shown in
Figure 1, no significant differences in the cellular uptake or sub-
cellular localization of the S413-PV peptide were observed be-
tween live and fixed HeLa cells. Under both experimental con-
ditions, the peptide exhibited a diffuse rather than punctate
distribution throughout the cytoplasm and nucleus. Interestingly,
nucleolar accumulation of the S413-PV peptide was observed,
similarly to what has been described for Tat peptide [16,27].
These results demonstrate that the S413-PV peptide is able to
efficiently penetrate into cells and accumulate inside the nucleus,
Figure 1 Effect of cell fixation on the cellular uptake and subcellular
distribution of the S413-PV peptide
HeLa cells were incubated with 1.0 µM rhodamine-labelled S413-PV peptide for 1 h at 37◦C.
The cells were then either immediately observed by confocal fluorescence microscopy (live
cells; left panel), or fixed with paraformaldehyde for subsequent analysis (right panel).
providing clear evidence that its cellular uptake and nuclear
accumulation cannot be attributed to fixation artifacts.
Cellular uptake of S413-PV peptide is concentration-dependent
and non-toxic
In order to assess the extent of peptide internalization, flow
cytometry analysis of cells exposed for 1 h to increasing concen-
trations of rhodamine-labelled S413-PV peptide was performed.
Since flow cytometry analysis does not discriminate between
membrane-associated and internalized peptide, before analysis
the cells were treated with trypsin to remove any surface-bound,
non-internalized peptide, which could result in an overestimation
of cellular uptake [16,17,25].
Flow cytometry analysis revealed that the number of cells
containing the peptide markedly increased with peptide concen-
tration, and also that the amount of peptide internalized by cells
increased with peptide dose, within the concentration range
examined (Figure 2a).
Additional studies conducted to evaluate the toxicity of the
S413-PV peptide demonstrated that its incubation with HeLa cells
up to a concentration of 2 µM does not result in any cytotoxicity
(Figure 2b).
S413-PV peptide cellular uptake is a very rapid and efficient process
To characterize further the uptake process of the S413-PV peptide,
the time course of peptide internalization was investigated. Flow
cytometry analysis of cells exposed to the peptide for different
times revealed that peptide uptake is a rapid and very efficient
process (Figure 3). Uptake of the peptide starts immediately upon
its addition to cells, reaching equilibrium after 30 min incubation.
The presence of 10% serum in the medium slightly retards
the cellular uptake of the peptide, most likely due to non-specific
electrostatic interactions of peptide molecules with serum com-
ponents.
Cellular uptake of S413-PV peptide requires energy
As a first approach to elucidate the mechanisms involved in the
cellular uptake of the S413-PV peptide, the temperature-sensitivity
and energy-dependence of the uptake process were evaluated.
Results obtained by confocal microscopy and flow cytometry
demonstrated that both low temperature and depletion of cellular
ATP dramatically decrease the number of cells containing the
peptide (Figure 4), strongly suggesting that the cellular uptake
of S413-PV peptide is mediated by an energy-dependent process.
Nonetheless, it is interesting to note that approx. 25% of the ATP-
depleted cells contained the peptide at levels similar to untreated
cells. Based on this observation, the additional contribution of
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Figure 2 Effect of the S413-PV peptide dose on its cellular uptake and
cytotoxicity
(a) Flow cytometry quantification of peptide uptake by HeLa cells incubated for 1 h at 37◦C
with increasing concentrations of rhodamine-labelled S413-PV peptide. (b) Viability of HeLa
cells exposed to increasing concentrations of S413-PV peptide. Cell viability was evaluated
by flow cytometry, based on propidium iodide exclusion by viable cells. Data are shown as
means +− S.D., based on triplicates of at least two independent experiments.
Figure 3 Time course of the cellular uptake of S413-PV peptide
HeLa cells were incubated with 1.0 µM rhodamine-labelled S413-PV peptide at 37◦C for different
time periods. The extent of peptide uptake was evaluated by flow cytometry in the absence (black
line) or presence (grey line) of 10 % fetal bovine serum in the medium. Data are shown as
means +− S.D., based on triplicates of at least two independent experiments.
an energy-independent mechanism to the cellular uptake of the
S413-PV peptide cannot be excluded.
Selective inhibition of different endocytic pathways does not
impair cellular uptake of S413-PV peptide
Given the results demonstrating that the cellular uptake of the
S413-PV peptide is an energy-dependent process, the potential role
of endocytosis in the uptake process was carefully evaluated.
Endocytosis may occur through several distinct mechanisms,
usually divided into two broad categories: phagocytosis, a pro-
cess restricted to specialized mammalian cells, and pinocytosis,
which occurs in all mammalian cells and encompasses macro-
pinocytosis, clathrin-mediated endocytosis, caveolae-mediated
endocytosis, as well as other less characterized clathrin- and
caveolae-independent endocytic pathways [28,29].
As a first approach to investigate the possible involvement of
the different endocytic pathways in the cellular uptake of the
S413-PV peptide, the effect of chlorpromazine (a known inhibi-
tor of clathrin-mediated endocytosis), of MβCD, nystatin or
filipin (which deplete or sequester membrane cholesterol, inhibit-
ing endocytic pathways dependent on lipid rafts, such as macro-
pinocytosis, caveolae- and clathrin-mediated endocytosis [29]),
of amiloride (which specifically blocks the Na+/H+ exchange
required for macropinocytosis [30]), and of cytochalasin D (an
inhibitor of F-actin elongation required for phagocytosis, macro-
pinocytosis and caveolar endocytosis [31]) was evaluated.
The results obtained by both confocal microscopy and
flow cytometry demonstrated that, among all the tested drugs,
only cytochalasin D had an inhibitory effect on the cellular uptake
of the S413-PV peptide (Figure 5).
Control experiments were performed to address the effect of
these drugs on the cellular uptake of transferrin, a ‘classical’
marker of clathrin-mediated endocytosis, as well as of LacCer,
a marker of raft/caveolae-mediated endocytosis. As shown, trans-
ferrin uptake was only inhibited by chlorpromazine (Figure 5b).
Although HeLa cells express low levels of caveolin-1, efficient
cellular uptake of LacCer was observed, which was inhibited
to different extents by the drugs that interfere with lipid rafts
(MβCD, filipin and nystatin), as well as by amiloride and cyto-
chalasin D (Figure 5b).
Taken together, the results from this systematic analysis
strongly suggest that endocytosis is not involved in the cellular
uptake of the S413-PV peptide, at the tested peptide concentration.
No significant cytotoxicity was associated with the treatment
of cells with the different drugs used in this study (results not
shown).
Cellular uptake of S413-PV peptide is not affected by
overexpression of dynamin-K44A dominant-negative mutant
To investigate further the role of endocytosis in the cellular uptake
of the S413-PV peptide, additional studies were performed by
addressing the effect of the overexpression of a dominant-negative
mutant of dynamin (dynamin-K44A) on peptide uptake.
Dynamin is a key regulator of membrane trafficking at the
cell surface, its GTPase activity being required for several forms
of endocytosis, including clathrin- and caveolae-mediated endo-
cytosis, phagocytosis and other less well-characterized clathrin-
and caveolae-independent endocytic pathways [28,32]. It has
been demonstrated previously [28,33–35] that overexpression of
dominant-negative mutants of dynamin that do not exhibit GTPase
activity, such as the dynamin-K44A mutant, can lead to im-
pairment of several endocytic pathways.
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Figure 4 Effect of low temperature and energy depletion on the uptake of S413-PV peptide by HeLa cells
(a, b) Flow cytometry and (c) confocal microscopy analysis of S413-PV peptide cellular uptake at low temperature and upon depletion of cellular ATP. HeLa cells were either pre-incubated at 4◦C or
pre-treated with energy-depletion medium for 1 h, and then incubated with 1.0 µM S413-PV peptide for 1 h under the same conditions, as described in the Experimental section. Confocal microscopy
analysis was performed in live cells. In (b), data are shown as means +− S.D., based on triplicates of at least two independent experiments.
As shown in Figure 6(a), co-transfection of HeLa cells with the
plasmids encoding dynamin-K44A and GFP (10:1 ratio) resulted
in the simultaneous expression of these two proteins in transfected
cells, thus allowing the easy and unambiguous identification
of cells expressing the dominant-negative mutant of dynamin by
analysis of GFP fluorescence.
Accordingly, cells expressing GFP, which also express the
dynamin-K44A dominant-negative mutant, were analysed for
their ability to internalize either the S413-PV peptide or fluor-
escently labelled transferrin, the latter being used as a control,
since its cellular uptake is known to occur through clathrin-
mediated endocytosis.
Our results demonstrated that the internalization of transferrin is
significantly reduced in cells overexpressing the dynamin-K44A
dominant-negative mutant, whereas the cellular uptake of the
S413-PV peptide is not affected by the expression of the dynamin-
K44A mutant (Figure 6b).
Since dynamin has been described to be required for several
pathways of endocytosis, these results clearly suggest that endo-
cytosis is not the mechanism responsible for the cellular uptake
of the S413-PV peptide at the tested concentration.
Cell surface proteoglycans facilitate S413-PV peptide uptake
Based on reports that cell surface heparan sulphate proteoglycans
are involved in the uptake of cell-penetrating peptides/fusion
proteins [13,27,36], experiments were performed to investigate
the role of these membrane components in the initial steps of inter-
action of the S413-PV peptide with cell membranes.
As a first approach to address this question, the competitive
effect of soluble heparin on the uptake of the S413-PV peptide
by HeLa cells was evaluated. Heparin mimics the GAG moieties
of some proteoglycans present at the cell surface, and has been
shown to bind Tat peptide very efficiently [37] and to impair the
cellular uptake of Tat fusion proteins [13,19,21,38].
Cellular uptake studies performed in the presence of heparin
demonstrated that concentrations of heparin as low as 2.5 µg/ml
are sufficient to completely block S413-PV peptide uptake (Fig-
ure 7), supporting the involvement of cell surface proteoglycans
as mediators of peptide–cell interaction.
To accurately examine whether the interaction of the S413-PV
peptide with biological membranes is dependent on the presence
of cell surface heparan sulphate proteoglycans, comparative
uptake studies were performed in CHO-K1 and pgs A-745 cell
lines. pgs A-745 is a mutant cell line derived from CHO-K1 that
is unable to synthesize proteoglycans, since it is defective in
xylosyltransferase I, an enzyme involved in the early steps of
GAG biosynthesis [39,40].
As shown in Figure 8, flow cytometry and confocal microscopy
analysis of peptide uptake by these two cell lines demonstrated
that cellular uptake of the S413-PV peptide is more extensive in
cells containing heparan sulphate proteoglycans (CHO-K1) when
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Figure 5 Cellular uptake of S413-PV peptide, transferrin and
lactosylceramide in the presence of drugs that affect endocytosis
(a) Confocal microscopy analysis of S413-PV peptide cellular uptake and (b) quantification by
flow cytometry of the extent of cellular uptake of S413-PV peptide, transferrin and LacCer in
the presence of drugs that inhibit different endocytic pathways. HeLa cells, pre-treated with the
different drugs for 30 min at 37◦C, were incubated in the presence of the drugs with
fluorescently labelled S413-PV peptide (1.0 µM for 1 h), transferrin (25 µg/ml for 30 min)
or BODIPY®-LacCer (500 nM for 10 min) at the same temperature, as described in the
Experimental section. Confocal microscopy (S413-PV peptide only) and flow cytometry analysis
was performed in live cells. Chlorpromazine (CHP) inhibits clathrin-mediated endocytosis,
MβCD, nystatin and filipin inhibit endocytic pathways dependent on lipid rafts by depleting
or sequestering membrane cholesterol, amiloride blocks the Na+/H+ exchange required for
macropinocytosis, and cytochalasin D (cyt D) inhibits F-actin elongation required for phago-
cytosis, macropinocytosis, caveolar endocytosis and other cellular processes. In (b), data are
shown as means +− S.D., based on triplicates of at least two independent experiments.
compared with mutant cells lacking proteoglycans (pgs A-745).
Nonetheless, it is important to note that the effect of proteoglycans
on facilitating the cellular uptake of S413-PV peptide was highly
dependent on peptide concentration. At low peptide concen-
trations, peptide uptake by cells lacking proteoglycans (pgs A-
745) was approx. 10-fold lower than that by cells containing
proteoglycans (CHO-K1), whereas, for higher peptide concen-
trations, smaller differences were observed (Figure 9).
Figure 6 Effect of dynamin-K44A dominant-negative mutant expression on
the cellular uptake of S413-PV peptide
(a) Analysis of the expression of HA-tagged dynamin-K44A (immunofluorescence, left panel)
and GFP (right panel) in HeLa cells co-transfected with plasmids encoding dynamin-K44A and
GFP (at a 10:1 ratio). (b) Uptake of fluorescently labelled transferrin (25 µg/ml, 15 min
incubation; control) or S413-PV peptide (1.0 µM, 1 h incubation) by HeLa cells co-transfected
with plasmids encoding dynamin-K44A mutant and GFP. Confocal microscopy analysis of
transferrin and peptide uptake was performed using live cells. The white arrows show cells that
express GFP and the dynamin-K44A dominant-negative mutant.
Although the presence of heparan sulphate proteoglycans at the
cell surface was not mandatory, the results from this comparative
analysis reinforce the importance of these membrane com-
ponents in the cellular uptake of the S413-PV peptide.
At low peptide concentrations, cellular uptake of the S413-PV
peptide is partially mediated by clathrin-dependent endocytosis
Results demonstrating that cell surface heparan sulphate proteo-
glycans play an important role in the cellular uptake of the S413-PV
peptide at low peptide concentrations, but not at high peptide con-
centrations, suggested the possible involvement of an additional
mechanism in the cellular uptake of the S413-PV peptide, which
would be dominant at low peptide concentrations.
To evaluate whether, at low S413-PV peptide concentrations,
endocytosis would also be involved in peptide uptake, the effect
of chlorpromazine and nystatin was assessed in CHO-K1 cells at
different peptide concentrations. Interestingly, at the lower peptide
concentrations tested (0.2 and 0.4 µM), a significant inhibition
of peptide uptake was observed upon cell treatment with chlor-
promazine (Figure 9), showing that, at these peptide concen-
trations, clathrin-mediated endocytosis is also involved in the
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Figure 7 Competitive inhibition of S413-PV peptide cellular uptake by
soluble heparin
Flow cytometry evaluation of the extent of peptide uptake in the presence of heparin, a soluble
glycosaminoglycan that mimics proteoglycan moieties ubiquitously present at cell surfaces.
HeLa cells were pre-treated with increasing concentrations of heparin for 30 min at 37◦C, and
then incubated for 1 h with 1.0 µM rhodamine-labelled S413-PV peptide in the presence of hep-
arin. Data are shown as means +− S.D., based on triplicates of at least two independent
experiments.
cellular uptake of the S413-PV peptide. At higher peptide concen-
trations, chlorpromazine had no effect on the cellular uptake of the
S413-PV peptide by CHO-K1 cells (Figure 9), similarly to what
was demonstrated previously in HeLa cells. Treatment of CHO-
K1 cells with nystatin, which was used to evaluate the involvement
of raft/caveolae-mediated endocytosis in the cellular uptake of the
S413-PV peptide, did not compromise peptide uptake, regardless
of the peptide concentration tested.
As controls, the effect of chlorpromazine and nystatin on the
cellular uptake of transferrin and LacCer was also evaluated in
CHO-K1 cells. Results were similar to those described previously
for HeLa cells, although a greater inhibition of LacCer uptake was
observed upon treatment of cells with nystatin (30% inhibition;
results not shown), most likely due to a higher caveolae-mediated
endocytic activity in CHO-K1 cells.
Overall, the results described herein support the existence of
two alternative mechanisms mediating the cellular uptake of the
S413-PV peptide: a GAG- and endocytosis-dependent mechanism
that is dominant at low peptide concentrations, and a GAG- and
endocytosis-independent mechanism that preferentially occurs at
high peptide concentrations.
DISCUSSION
Accumulated studies that fixation procedures are on the basis of
artifactual observations of intracellular and nuclear accumulation
of some cell-penetrating peptides have prompted a critical re-
evaluation of the mechanisms responsible for the cellular uptake
of these peptides. Despite the fact that some controversy still exists
concerning certain mechanistic aspects of their cellular uptake,
cell-penetrating peptides have been extensively used for bio-
technological purposes, particularly for the in vitro and in vivo
delivery of proteins, with unquestionable success.
The studies described in the present paper were aimed at clarify-
ing the mechanisms involved in the cellular uptake of the
dermaseptin-derived S413-PV cell-penetrating peptide. Compara-
tive analysis of the cellular uptake and subcellular localization
of the S413-PV peptide in live and fixed cells demonstrated that
the S413-PV peptide is able to accumulate inside cells through
a rapid and very efficient process, irrespectively of cell fixation.
Moreover, the diffuse cytoplasmic distribution of the S413-PV
peptide was shown to be independent of fixation artifacts, unlike
that reported previously for other cell-penetrating peptides [3,16].
Nonetheless, the present study demonstrates that cellular uptake
of the S413-PV peptide occurs through a temperature-sensitive and
energy-dependent process, in contrast with what has been recently
reported for this peptide [22]. These conflicting results stem from
the fact that initial reports on the cellular uptake of this peptide,
as well as of other cell-penetrating peptides, relied on fluor-
escence microscopic analysis of fixed cells, recurrently reflecting
artifactual observations caused by an intracellular redistribution
of membrane-bound peptide molecules upon cell fixation. Arti-
factual observations are particularly misleading under experi-
mental conditions in which cellular uptake is blocked or severely
compromised, such as low temperature and energy depletion, as
was the case in the initial study on the cellular uptake of the S413-
PV peptide [22]. In fact, similar observations of a temperature-
insensitive and energy-independent cellular uptake of the S413-PV
peptide were made by us, when working with fixed cells (results
not shown).
These results underline the importance of this and other
studies, in which the mechanisms involved in the uptake of
cell-penetrating peptides (and/or fusion proteins containing these
peptides) are carefully re-evaluated using improved procedures
that minimize artifacts, either by avoiding cell fixation and/or by
enzymatically removing membrane-bound, but non-internalized,
peptide/fusion protein [16,17,25]. Accordingly, it is interesting to
observe that several studies performed by using these improved
methods revealed that some of the so-called cell-penetrating
peptides are in fact internalized into cells by endocytosis
[14,15,19–21,41].
In this context, the possible involvement of endocytosis in the
cellular uptake of the S413-PV peptide was thoroughly inves-
tigated by analysing peptide uptake in the presence of drugs that
selectively compromise different cellular processes, as well as
that in cells overexpressing a dominant-negative mutant of
dynamin.
Taking into consideration that the cellular uptake of the S413-PV
peptide occurs through a temperature-sensitive and energy-depen-
dent mechanism, inhibition of peptide uptake by cytochalasin D
might support a role for endocytosis in the internalization process.
However, the lack of inhibition observed for all the other tested
drugs, which also compromise the endocytic pathways that are
affected by cytochalasin D, is not consistent with this hypothesis.
Most likely, the inhibition of peptide uptake by cytochalasin D is
an indirect consequence of its effect on other cellular processes
in which actin is also involved. The additional observation that
uptake of the S413-PV peptide is not inhibited upon cell treatment
with metabolic inhibitors that non-specifically block all endocytic
pathways (sodium azide, sodium fluoride, antimycin A; results not
shown), as well as the diffuse, rather than punctate, intracellular
distribution of the peptide, reinforce further that, under these
experimental conditions, endocytosis is not involved in the cel-
lular internalization of the S413-PV peptide.
The overexpression of dominant-negative mutants of proteins
has been successfully used to study different cellular processes,
including endocytosis. In the present study, a dominant-negative
mutant of dynamin (dynamin-K44A) was used as an alternative
approach to investigate further the role of endocytosis in the
cellular uptake of the S413-PV peptide. Although dynamin was ini-
tially described to be required for clathrin-mediated endocytosis,
additional evidence has implicated dynamin in several other
endocytic pathways, including caveolae-mediated endocytosis,
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Figure 8 Uptake of S413-PV peptide by cells genetically deficient in proteoglycan biosynthesis
Wild-type CHO-K1 cells and pgs A-745 mutant cells, deficient in proteoglycan biosynthesis, were incubated for 1 h at 37◦C with increasing concentrations of rhodamine-labelled S413-PV peptide.
(a, b) Flow cytometry analysis of S413-PV peptide uptake by CHO-K1 and pgs A-745 cell lines. (c) Quantification of the uptake of fluorescently labelled S413-PV peptide by CHO-K1 and pgs A-745
cells. Data are shown as means +− S.D., based on triplicates of at least two independent experiments. (d) Confocal microscopy analysis of S413-PV peptide uptake by CHO-K1 and pgs A-745 cells.
Microscopy analysis of peptide uptake was performed in live cells.
phagocytosis and clathrin- and caveolae-independent pathways
[28,32].
Therefore the observation that overexpression of the dynamin-
K44A dominant-negative mutant significantly inhibits the extent
of transferrin internalization, whereas it has no effect on the
cellular entry of the S413-PV peptide, clearly indicates that endo-
cytosis is not involved in its cellular uptake. These results are
in agreement with those described above regarding the effect of
several drugs that selectively inhibit different endocytic pathways
on peptide uptake, which collectively exclude endocytosis as
being the mechanism responsible for the efficient cellular uptake
of the S413-PV peptide.
Previous reports have shown that heparan sulphate proteo-
glycans are absolutely required for the cellular uptake of full-
length Tat and Tat-fusion proteins [13,14,27]. In view of these
findings, the dramatic inhibition of cellular uptake of the S413-PV
peptide by low heparin concentrations reported in the present
study strongly suggests that the interactions between the positively
charged peptide and highly negatively charged membrane com-
ponents, such as the GAG moieties of cell surface proteoglycans,
play an important role in the overall process of cellular uptake of
this peptide [36]. Although this observation may also reflect non-
specific electrostatic interactions between the S413-PV peptide
and heparin, it has been described that heparin blocks uptake of
cell-penetrating peptides and peptide conjugates more efficiently
than other negatively charged soluble GAGs, such as chondroitin
sulphates [13,21], most likely indicating that the strong interaction
between cell-penetrating peptides, including the S413-PV peptide,
and heparin involves some structural requirements.
More interestingly, results from the comparative analysis of
cellular uptake of the S413-PV peptide by normal and genetically
modified cells that are deficient in proteoglycan biosynthesis
clearly demonstrate that heparan sulphate proteoglycans poten-
tiate the cellular uptake of the S413-PV peptide, although their pre-
sence at the cell surface is not mandatory. In fact, the effect of
proteoglycans on the cellular uptake of the S413-PV peptide was
c© 2005 Biochemical Society
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Figure 9 Effect of S413-PV peptide concentration on the mechanisms of
cellular uptake
Flow cytometry quantification of the effect of chlorpromazine and nystatin on the extent of
S413-PV peptide uptake by CHO-K1 cells. Cells were incubated for 1 h at 37◦C, with increasing
concentrations of rhodamine-labelled S413-PV peptide. Data are shown as means +− S.D., based
on triplicates of at least two independent experiments.
shown to be relevant only at low peptide concentrations, whereas
at high peptide concentrations almost no differences were ob-
served between cells containing, or not, proteoglycans.
Although these results may also reflect the role of proteoglycans
in promoting peptide binding to cell membranes, which pre-
sumably is not a limiting step at high peptide concentrations,
studies performed to address the involvement of endocytosis in the
cellular uptake of the S413-PV peptide at low concentrations have
demonstrated that two mechanisms are responsible for the cel-
lular uptake of this peptide: a GAG- and endocytosis-dependent
mechanism, which is dominant at low peptide concentrations,
and a GAG- and endocytosis-independent mechanism that occurs
preferentially at high peptide concentrations.
Despite the important role that the GAG- and endocytosis-
dependent mechanism plays in peptide uptake at low concen-
trations, it should be highlighted that, under experimental con-
ditions leading to efficient uptake of the S413-PV peptide by the
majority of cells, the contribution of this mechanism is negligible,
and the GAG- and endocytosis-independent mechanism of peptide
uptake is clearly prevalent.
A possible explanation for the observations of a dominant endo-
cytosis-independent mechanism only at high peptide concen-
trations is that a critical concentration of peptide at the membrane
has to be achieved in order to elicit the events that lead to the endo-
cytosis-independent translocation of the S413-PV peptide across
biological membranes. Work by Ha¨llbrink et al. [42], demon-
strating that the extent of cellular uptake of the Penetratin peptide
is dependent on the peptide-to-cell ratio rather than on the molar
concentration of the peptide, argues in favour of this hypothesis.
In addition, it is interesting to note that the S413-PV peptide
undergoes significant conformational changes in the presence
of lipid vesicles of various compositions, which are consistent
with the formation of helical structures (M. Mano, F. Gavilanes,
S. Simo˜es and M. C. Pedroso de Lima, unpublished work).
Similar results have also been reported for other peptides, such as
Penetratin and Pep-1 [43,44], which have been shown to penetrate
cells independently of endocytosis. Moreover, we have observed
recently that such conformational changes occur concomitantly
with the penetration of the S413-PV peptide into the lipid bilayer,
strongly suggesting that the resulting helical structures may be of
critical importance for the non-endocytic cellular uptake of the
peptide (M. Mano, F. Gavilanes, S. Simo˜es and M. C. Pedroso de
Lima, unpublished work).
To our knowledge, the findings in the present study provide the
first systematic report that the peptide concentration in itself may
determine the mechanism by which uptake of cell-penetrating
peptides occurs and, consequently, their intracellular fate.
Although the main mechanism responsible for the efficient
uptake of the S413-PV cell-penetrating peptide observed at high
peptide concentrations remains elusive, the results presented in
this study demonstrate that this mechanism is distinct from endo-
cytosis. Studies are currently in progress in our laboratory aimed
at investigating whether this mechanism will correlate with an
increased capacity of the S413-PV peptide to mediate the intra-
cellular delivery of molecules of pharmacological interest, includ-
ing drugs, proteins and nucleic acids.
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